- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04894916
My Diabetes Care Mobile: A Usability Study
October 18, 2022 updated by: William Martinez, MD, MS, Vanderbilt University Medical Center
The My Diabetes Care Patient Portal Intervention for Mobile Devices: A Usability Study
The purpose of this study is to conduct a prospective, longitudinal study on the My Diabetes Care mobile (MDC-m) intervention to assess usage patterns, user experience, and to uncover errors in functionality prior to a larger interventional trial.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Up to 65 adult patients with type 2 diabetes mellitus will be enrolled and given access to My Diabetes Care mobile (MDC-m).
My Diabetes Care mobile (MDC-m) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management.
MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
Patients will be invited by mail to be screened for enrollment in the study.
Interested patients will be able to complete an electronic consent form and enroll online via Research Electronic Data Capture (REDCap™) version 5.0.8.
Study participants will complete questionnaires electronically via email using REDCap™ at two time points: baseline (T0) and one-month follow-up (T1).
Participants will complete an baseline questionnaire (T0) including basic demographic questions, items about computer usage and internet access, and validated measures of health literacy and eHealth literacy.
Each participant will have access to the MDC-m for 1 month.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 Diabetes Mellitus
- Currently taking at least one medication for diabetes
- Age 21 or over
- Able to speak and read in English
- Reliable access to a smartphone or tablet with internet access
- Active VUMC patient web portal (known as My Health At Vanderbilt) account
Exclusion Criteria:
- Residing in a long term care facility
- Medical condition that affects my memory or ability to think.
- Severe visual impairment
- Patients with unintelligible speech (e.g., dysarthria)
- Currently participating in another diabetes-related research study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: My Diabetes Care Mobile (MDC-m)
Patients have access to a patient web portal embedded with the My Diabetes Care Mobile (MDC-m) intervention.
|
My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management.
MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Usability
Time Frame: One-month follow-up
|
The System Usability Scale (SUS) is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree).
The ten items are scored on a five-point Likert scale.
The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best).
Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.
The SUS has been used in several studies of patient facing health information technology (the article describing its psychometric properties has been cited over 500 times) and has excellent internal consistency reliability (Cronbach's alpha of 0.91).
|
One-month follow-up
|
|
System Usage Data
Time Frame: One-month follow-up
|
Self-reported usage of My Diabetes Care to include total number of participants who visited MDC-m during the study period and total number of participants with who used MDC-m for 10 minutes or more during the study period.
|
One-month follow-up
|
|
User Experience
Time Frame: One-month follow-up
|
Unique study specific items to assess participants' perspectives on the usefulness of particular My Diabetes Care features and functionality.
|
One-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Diabetes Knowledge
Time Frame: Baseline to one-month follow-up
|
The Short Diabetes Knowledge Instrument (SDKI) is a valid measure of diabetes knowledge with an emphasis on controlling blood glucose through diet, recognizing symptoms of abnormal blood glucose, and using healthy eating to prevent complications.
It also includes items on foot care and the importance of physical activity for preventing cardiovascular complications.
The SDKI is a uni-dimensional, 13-item scale with scores ranging from 0 to 13 (number of items answered correctly).
SDKI demonstrated good internal consistency reliability (Cronbach's alpha 0.73) in a multi-ethnic sample of older adults suggesting the instrument can be used to measure diabetes knowledge in diverse populations (Quandt et al.
Diabetes Educator, 2014).
|
Baseline to one-month follow-up
|
|
Change in Diabetes Self-Efficacy
Time Frame: Baseline to one-month follow-up
|
The Perceived Diabetes Self-Management Scale (PDSMS) is a valid measure of diabetes self-efficacy (i.e., how confident they feel about their ability to carry out multiple self management tasks).
The uni-dimensional, 8-item scale is scored on a five-point Likert scale.
The total PDSMS score can range from 8 to 40, with higher scores indicating more confidence in self-managing one's diabetes.
|
Baseline to one-month follow-up
|
|
Change in Number of Participants That Correctly Identified Definitions and Goal Ranges for Diabetes Health Measures
Time Frame: Baseline to one-month follow-up
|
Unique study specific items to assess participants' knowledge of measures of diabetes health status (i.e., Hemoglobin A1C, blood pressure, low-density lipoprotein, and flu vaccination status).
Each multiple choice item has one correct answer and the unit of measure is the number of participants that correctly answered each item.
|
Baseline to one-month follow-up
|
|
Change in Diabetes Distress
Time Frame: Baseline to one-month follow-up
|
The Problem Areas in Diabetes Scale (PAID-5) is a valid measure of diabetes distress.
The five-item, uni-dimensional scale has scores that range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress.
The PAID-5 has excellent excellent internal consistency reliability (Cronbach's alpha 0.86) and is associated with measures of depression and hemoglobin A1c.
|
Baseline to one-month follow-up
|
|
Change in Diabetes Attitudes
Time Frame: Baseline to one-month follow-up
|
Unique study specific items to assess participants' attitudes toward social comparisons (2 items) and goal-based comparisons (2 items) regarding their diabetes health status.
Each items is scored on a 5-point Likert scale from '1=strongly disagree' to '5=strongly agree'.
|
Baseline to one-month follow-up
|
|
Change in Diabetes Readiness for Change
Time Frame: Baseline to one-month follow-up
|
Four-item assessment of stage of change based on the Transtheoretical Model (TTM) of behavior change.
It includes questions one item each assessing the participants stage of change for: (1) physical activity, (2) medication management, (3) glucose self-monitoring, and (4) diet.
There are five response options per item that categorize the participants' current TTM stage of change for the item: (a) Precontemplation, (b) Contemplation, (c) Preparation, (d) Action, and (e) Maintenance.
|
Baseline to one-month follow-up
|
|
Change in Diabetes Self-Care (General Diet Adherence)
Time Frame: Baseline to one-month follow-up
|
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items).
The general diet subscale is used to assess general diet adherence.
The instrument is based on the self-reported days completing recommended activities during the past 7 days.
An example item includes "How many of the last SEVEN DAYS have you followed a healthful eating plan?"
The general diet subscale score is the mean number of days for the 2 items in the subscale.
The score range is from 0 days (worst) to 7 days (best).
|
Baseline to one-month follow-up
|
|
Change in Diabetes Self-Care (Specific Diet Adherence)
Time Frame: Baseline to one-month follow-up
|
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items).
The general diet subscale is used to assess general diet adherence.
The instrument is based on the self-reported days completing recommended activities during the past 7 days.
An example item includes "How many of the last SEVEN DAYS have you followed a healthful eating plan?"
The general diet subscale score is the mean number of days for the 2 items in the subscale.
The score range is from 0 days (worst) to 7 days (best).
|
Baseline to one-month follow-up
|
|
Change in Diabetes Self-Care (Exercise Adherence)
Time Frame: Baseline to one-month follow-up
|
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items).
The exercise subscale is used to assess exercise adherence.
The instrument is based on the self-reported days completing recommended activities during the past 7 days.
An example item includes "On how many of the last SEVEN DAYS did you participate in at least 30 minutes of physical activity?"
The exercise subscale score is the mean number of days for the 2 items in the subscale.
The score range is from 0 days (worst) to 7 days (best).
|
Baseline to one-month follow-up
|
|
Change in Diabetes Self-Care (Self-Monitoring of Blood Glucose Adherence)
Time Frame: Baseline to one-month Follow-up
|
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items).
The blood-glucose testing subscale is used to assess self-monitoring of blood glucose adherence.
The instrument is based on the self-reported days completing recommended activities during the past 7 days.
An example item includes "On how many of the last SEVEN DAYS did you test your blood sugar?"
The blood-glucose testing subscale is the mean number of days for the 2 items in the subscale.
The score range is from 0 days (worst) to 7 days (best).
|
Baseline to one-month Follow-up
|
|
Change in Medication Adherence
Time Frame: Baseline to one-month follow-up
|
The Adherence to Refills and Medications Scale is a reliable and valid measure of medication adherence.
The 12-item ARMS has good internal consistency reliability (α=0.81).
Responses range from 1="none of the time" to 4="all of the time," and are summed to produce an overall adherence score ranging from 12-48, with higher scores representing more problems with medication adherence.
|
Baseline to one-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: William Martinez, MD, MS, Vanderbilt University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 12, 2021
Primary Completion (Actual)
August 27, 2021
Study Completion (Actual)
August 27, 2021
Study Registration Dates
First Submitted
May 11, 2021
First Submitted That Met QC Criteria
May 18, 2021
First Posted (Actual)
May 20, 2021
Study Record Updates
Last Update Posted (Actual)
November 10, 2022
Last Update Submitted That Met QC Criteria
October 18, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202268
- 1R03DK119735 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
After study results are posted on clinical trials and published in a peer-reviewed journal, de-identified individual participant data that underlie the results reported will be available upon requests made to the principal investigator and ending after 36 months after publication.
IPD Sharing Time Frame
Deidentified individual participant data that underlie the results reported will be available after publication in a peer reviewed journal and posted on clinical trials and ending after 36 months after publication.
IPD Sharing Access Criteria
Researchers should provide a methodologically sound proposal to achieve their proposed aims.
Proposals may be submitted to the principal investigator up to 36 months following publication.
To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsNot yet recruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on My Diabetes Care Mobile (MDC-m)
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2United States
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedDiabetes Mellitus, Type 2United States
-
Mohd Khairul Zul Hasymi FirdausPrince of Songkla UniversityCompletedDiabetes Mellitus, Type 2Malaysia
-
Selma SahinActive, not recruitingDiabetes Mellitus, Diabetic Foot Diabetic Foot CareTurkey (Türkiye)
-
VA Office of Research and DevelopmentCompleted
-
Sanko UniversityUniversity of GaziantepCompletedBreast CancerTurkey (Türkiye)
-
University of PittsburghNational Institutes of Health (NIH)CompletedDiabetes Mellitus, Type 2United States